Circulating free DNA in a screening program for early colorectal cancer detection

Tumori

Volumn 100, Issue 2, 2014, Pages 115-121

  Perrone, Federica ^a   Lampis, Andrea ^a   Bertan, Claudia ^a   Verderio, Paolo ^a   Ciniselli, Chiara M ^a   Pizzamiglio, Sara ^a   Frattini, Milo ^b   Nucifora, Martina ^b   Molinari, Francesca ^b   Gallino, Gianfranco ^a   Gariboldi, Manuela ^a,c   Meroni, Emanuele ^a   Leo, Ermanno ^a   Pierotti, Marco A ^a   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF PATHOLOGY   (Switzerland)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Circulating free DNA; Colorectal cancer; Early diagnosis; Plasma

Indexed keywords

CIRCULATING FREE DNA; DNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER SCREENING; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; GENE MUTATION; HIGH GRADE INTRAEPITHELIAL NEOPLASIA IN ADENOMA; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; ONCOGENE K RAS; PREDICTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MUTATION; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84901468108     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1491.16389     Document Type: Article

References (34)

1. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, Del Rio M, Molina F: Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res, 38: 6159-6175, 2010.
2. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P: About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta, 313: 139-142, 2001. (Pubitemid 33016703)
3. García-Olmo DC, Domínguez C, García-Arranz M, Anker P, Stroun M, García-Verdugo JM, García-Olmo D: Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res, 70: 560-567, 2010.
4. Boni L, Cassinotti E, Canziani M, Dionigi G, Rovera F, Dionigi R: Free circulating DNA as possible tumour marker in colorectal cancer. Surg Oncol, 16: S29-31, 2007.
5. Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A, Verdecchia GM, Amadori D: Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res, 12: 6985-6988, 2006. (Pubitemid 44974493)
6. Danese E, Montagnana M, Minicozzi AM, De Matteis G, Scudo G, Salvagno GL, Cordiano C, Lippi G, Guid GC: Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. Clin Chem Lab Med, 48: 1665-1668, 2010.
7. Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L, Sozzi G, Bertario L, Leo E, Pilotti S, Pierotti MA: Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett, 263: 170-181, 2008.
8. Frattini M, Gallino G, Signoroni S, Balestra D, Battaglia L, Sozzi G, Leo E, Pilotti S, Pierotti MA: Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann N Y Acad Sci, 1075: 185-190, 2006. (Pubitemid 44532783)
9. Agostini M, Pucciarelli S, Enzo MV, Del Bianco P, Briarava M, Bedin C, Maretto I, Friso ML, Lonardi S, Mescoli C, Toppan P, Urso E, Nitti D: Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol, 18: 2461-2468, 2011.
10. Zitt M, Müller HM, Rochel M, Schwendinger V, Zitt M, Goebel G, Devries A, Margreiter R, Oberwalder M, Zeillinger R, Ofner D: Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers, 25: 159-165, 2008.
11. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A: Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res, 18: 1177-1185, 2012.
12. Lecomte T, Ceze N, Dorval E, Laurent-Puig P: Circulating free tumor DNA and colorectal cancer. Gastroenterol Clin Biol, 34: 662-681, 2010.
13. Wang JY, Hsieh JS, Chang MY, Huang TJ, Chen FM, Cheng TL, Alexandersen K, Huang YS, Tzou WS, Lin SR: Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg, 28: 721-726, 2004. (Pubitemid 39097133)
14. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 486: 532-536, 2012.
15. Parente F, Marino B, Ardizzoia A, Ucci G, Ilardo A, Limonta F, Villani P, Moretti R, Zucchi A, Cremaschini M, Pirola ME: Impact of a population-based colorectal cancer screening program on local health services demand in Italy: a 7-year survey in a northern province. Am J Gastroenterol, 106: 1986-1993, 2011.
16. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Jr. Diaz LA, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B: Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA, 102: 16368-16373, 2005. (Pubitemid 41688920)
17. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U: Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol, 21: 3902-3908, 2003. (Pubitemid 46606202)
18. Bearzatto A, Conte D, Frattini M, Zaffaroni N, Andriani F, Balestra D, Tavecchio L, Daidone MG, Sozzi G: p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res, 8: 3782-3787, 2002. (Pubitemid 35424770)
19. Hollander M, Wolfe DA: The two-sample dispersion problem and other two-sample problems, In: Nonparametric statistical methods, second ed, pp 141-188, John Wiley & Sons, New York, 1999.
20. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 143: 29-36, 1982. (Pubitemid 12142173)
21. Hosmer DW Jr, Lemeshow S: Assessing the fit of the model. In: Applied logistic regression, second ed, pp 143-202, John Wiley & Sons, New York, 2000.
22. Durrleman S, Simon R: Flexible regression models with cubic splines. Stat Med, 8: 551-561, 1989. (Pubitemid 19116001)
23. Brown BW, Russell K: Methods correcting for multiple testing: operating characteristics. Stat Med, 16: 2511-2528, 1997. (Pubitemid 27490058)
24. van der Vaart M, Pretorius PJ: Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem, 43: 26-36, 2010.
25. Lee TH, Montalvo L, Chrebtow V, Busch MP: Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion, 41: 276-282, 2001. (Pubitemid 32220522)
26. Mead R, Duku M, Bhandari P, Cree IA: Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer, 105: 239-245, 2011.
27. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A; COLONPREV Study Investigators: Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med, 366: 697-706, 2012.
28. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Jr Diaz LA: Circulating mutant DNA to assess tumor dynamics. Nat Med, 14: 985-990, 2008.
29. Cooke S, Campbell P: Circulating DNA and next-generation sequencing. Recent Results Cancer Res, 195: 143-149, 2012.
30. Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD: Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst, 92: 918-923, 2000. (Pubitemid 30429192)
31. Gormally E, Vineis P, Matullo G, Veglia F, Caboux E, Le Roux E, Peluso M, Garte S, Guarrera S, Munnia A, Airoldi L, Autrup H, Malaveille C, Dunning A, Overvad K, Tjønneland A, Lund E, Clavel-Chapelon F, Boeing H, Trichopoulou A, Palli D, Krogh V, Tumino R, Panico S, Bueno-de-Mesquita HB, Peeters PH, Pera G, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Hallmans G, Day NE, Key TJ, Saracci R, Kaaks R, Riboli E, Hainaut P: TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res, 66: 6871-6876, 2006. (Pubitemid 44085648)
32. Ramirez JL, Sarries C, de Castro PL, Roig B, Queralt C, Escuin D, de Aguirre I, Sanchez JM, Manzano JL, Margelí M, Sanchez JJ, Astudillo J, Taron M, Rosell R: Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett, 193: 207-216, 2003. (Pubitemid 36428904)
33. Chi S, Kitanaka C, Noguchi K, Mochizuki T, Nagashima Y, Shirouzu M, Fujita H, Yoshida M, Chen W, Asai A, Himeno M, Yokoyama S, Kuchino Y: Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene, 18: 2281-2290, 1999. (Pubitemid 29186929)
34. Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, Zanutto S, Perrone F, Camerini T, Gallino G, Verderio P, Leo E, Pilotti S, Gariboldi M, Pierotti MA: miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res, 10: 504-515, 2012.